Towards automation of breast cancer screening

therapixel.com
Entrepreneurs

Matthieu Leclerc-Chalvet
Pierre Fillard

Elaia Team

Laurent Kott

Related articles

Therapixel announces fundraising of 15 Mā‚¬ in series B to deploy MammoScreenĀ® 2D/3D

The Company will accelerate the commercial deployment of its ArtificialĀ Intelligence reading solution for 2D/3D mammography, with a focus onĀ the United StatesĀ 

2022.05.12Ā / 3min read.

Therapixel receives FDA 510(k) clearance for MammoScreenTM

MammoScreenTM, the explainable and actionable artificial intelligence (AI) based software assisting Radiologists in reading screening mammograms, received 510(k) clearance K192854 from the U.S. Food and Drug Administration (FDA).

2020.07.09Ā / 3min read.